Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Waldenström macroglobulinemia.

Irene M Ghobrial1, Thomas E Witzig

  • 1Division of Hematology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA. witzig.thomas@mayo.edu

Current Treatment Options in Oncology
|April 30, 2004
PubMed
Summary

Waldenström macroglobulinemia (WM) is a rare blood cancer. While treatable, it requires careful balancing of risks and benefits, with rituximab emerging as a key therapy alongside chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026
Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026
Same author

New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.

Blood cancer discovery·2026
Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026
Same author

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.

American journal of hematology·2026
Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenström macroglobulinemia (WM) is a rare, low-grade lymphoproliferative disorder.
  • Characterized by IgM monoclonal protein and infiltration of marrow by malignant lymphocytes.

Purpose of the Study:

  • To review current treatment strategies for Waldenström macroglobulinemia.
  • To highlight the role of emerging therapies and the need for careful risk-benefit assessment.

Main Methods:

  • Literature review of existing treatment options for WM.
  • Analysis of therapeutic benefits and toxicities of available agents.

Main Results:

  • Chlorambucil remains a useful option, particularly for older patients.
  • Rituximab shows positive responses with acceptable toxicity and no myelosuppression, often used in combination therapy.
  • Interferon, corticosteroids, and stem cell transplantation are other therapeutic considerations.

Conclusions:

  • WM treatment requires balancing efficacy and toxicity.
  • Rituximab represents a significant advancement in WM therapy.
  • Further comparative data are needed to establish optimal treatment protocols.

Related Experiment Videos